4//SEC Filing
Lewis Karen 4
Accession 0001127602-23-012595
CIK 0001492422other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 4:52 PM ET
Size
8.3 KB
Accession
0001127602-23-012595
Insider Transaction Report
Form 4
Lewis Karen
Chief People Officer
Transactions
- Exercise/Conversion
Common Stock
2023-04-03$34.11/sh+5,000$170,550→ 46,430 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-04-03−5,000→ 111,000 totalExercise: $34.11Exp: 2030-05-03→ Common Stock (5,000 underlying) - Sale
Common Stock
2023-04-03$75.00/sh−5,000$375,000→ 41,430 total
Footnotes (2)
- [F1]This is a scheduled exercise and sale from an established 10b5-1 plan.
- [F2]This stock option was granted on 5/4/2020 and has a four year vesting period. 25% vest one year from grant date. The remaining 75% vest monthly over the last three years of the four year vesting period.
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Entity typeother
Related Parties
1- filerCIK 0001814304
Filing Metadata
- Form type
- 4
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 4:52 PM ET
- Size
- 8.3 KB